Authera is dedicated to the discovery and development of novel therapeutic biologics, and is offering a unique platform as a fee-for-service or as part of industrial collaboration or co-development. The high-end technology platform is used to guide design and selection of molecules with the ability to directly or indirectly engage the neonatal Fc receptor (FcRn) - a key half-life regulator of IgG antibodies and albumin. The platform combines biochemical and cellular assays with transgenic mouse models used to dissect the binding and cellular transport properties of FcRn-targeted molecules, predictive for vivo pharmacokinetic behavior. The platform is also ideal for investigation of FcRn antagonists. Authera is science-driven and has two lead preclinical development programs, with undisclosed targets and indications.